1. 498PPhase I/II study of valproic acid (VPA) and short-course radiotherapy (SCRT) plus capecitabine (CAP) as preoperative treatment in low-moderate risk rectal cancer (V-shoRT-R3). (23rd October 2018) Authors: Budillon, A; Delrio, P; Pecori, B; Tatangelo, F; Di Gennaro, E; Romano, C; D'Angelo, V; Marone, P; Granata, C; Cavalacanti, E; De Stefano, A; Pace, U; Bianco, F; Petrillo, A; Lastoria, S; Botti, G; Muto, P; Perrone, F; Piccirillo, M C; Avallone, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cardioprotective effects of PCSK9 inhibitor evolocumab against doxorubicin-trastuzumab sequential treatments and ipilimumab-induced cardiotoxicity: the role of MyD88/NF-KB/mTORC1 pathways. (25th November 2020) Authors: Quagliariello, V; Caronna, A; Lombari, C; Bonelli, A; Conforti, G; Botti, G; Maurea, N Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Evolocumab, a PCSK9 inhibitor, co-incubated with doxorubicin and trastuzumab reduces death of cardiomyocytes through reduction of MyD88-NLRP3-NF-kB-mTORC1. (14th October 2021) Authors: Quagliariello, V; Bonelli, A; Paccone, A; Buccolo, S; Iovine, M; Conforti, G; Botti, G; Maurea, N Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Invasive electrophysiological study in the Jervell and Lange-Nielsen syndrome. Issue 1 (January 1982) Authors: Botti, G; Bonatti, V Journal: Heart Issue: Volume 47:Issue 1(1982) Page Start: 106 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Ipilimumab and Nivolumab exertes cardiotoxic and pro-fibrotic effects in mice through the overexpression of NLRP3 inflammasome, chemokines and leukotrienes. (14th October 2021) Authors: Quagliariello, V; Passariello, M; Rea, D; Barbieri, A; Buccolo, S; Iovine, M; Bonelli, A; Caronna, A; Botti, G; De Lorenzo, C; Maurea, N Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Oxidized Low-Density Lipoproteins increases nivolumab-induced cardiotoxicity through TLR4/NF-KB and NLRP3 pathways. (14th October 2021) Authors: Quagliariello, V; Bonelli, A; Paccone, A; Buccolo, S; Iovine, M; Botti, G; Maurea, N Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P616Cardioprotective effects of nanoemulsions loaded with natural anti-inflammatory molecules against doxorubicin-induced cardiotoxicity in cardiomyocytes. (28th August 2018) Authors: Maurea, N; Quagliariello, V; Vecchione, R; Di Cicco, C; De Capua, A; Coppola, C; Piscopo, G; Paciello, R; Iaffaioli, R V; Netti, P A; Botti, G Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. SGLT2 inhibitor dapagliflozin against anthracycline and trastuzumab-induced cardiotoxicity: the role of MYD88, NLRP3, Leukotrienes/Interleukin 6 axis and mTORC1 /Fox01/3a mediated apoptosis. (25th November 2020) Authors: Quagliariello, V; De Laurentiis, M; Rea, D; Barbieri, A; Monti, M.G; Botti, G; Maurea, N Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) improves ejection fraction and longitudinal strain in mice treated with doxorubicin through NLRP3. (14th October 2021) Authors: Quagliariello, V; Bonelli, A; Paccone, A; Buccolo, S; Iovine, M; Rea, D; Cerrone, F; Botti, G; Maurea, N Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. TheSGLT-2 inhibitor dapagliflozin ehnanced the anticancer activities and exerts cardioprotective effects during exposure to ipilimumab through NLRP3 inflammasome and pro-fibrotic cytokines. (14th October 2021) Authors: Maurea, N; Quagliariello, V; Bonelli, A; Paccone, A; Conforti, G; Caronna, A; Buccolo, S; Iovine, M; Cerrone, F; Botti, G Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗